Macrophage Pharma Expands Executive Team with Chief Scientific Officer and Chief Technology Officer

Key hires enhance management for next development phase

09 January 2020, Windsor, UK: Macrophage Pharma Limited (“MPL”), a biotech company focused on the discovery and development of next-generation immunomodulatory small molecules inducing transcriptional reprogramming  of macrophage function to combat cancer and other diseases, announced today that it has appointed Venkat Reddy PhD as Chief Scientific Officer (CSO) and David Moffat PhD, MPL co-founder and former director of chemistry, as Chief Technology Officer (CTO).

Commenting on the appointments, Dr Søren Bregenholt, MPL Chief Executive Officer said: “On behalf of the executive team I am pleased to welcome Venkat as CSO and David in his new role as CTO as the Company progresses to its next stage of development. Venkat’s deep understanding of pharmaceutical R&D, extensive experience in drug discovery, translational research and early development combined with David’s profound knowledge of our foundation Esterase Sensitive MotifTM (ESMTM) technology, which he co-invented, and drug discovery, will continue to be invaluable as we advance towards clinical trials this year, diversify the technology platform and build out the pipeline to address multiple indications.”

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH